Filtered By:
Specialty: Drugs & Pharmacology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 688 results found since Jan 2013.
Discovery and development of Factor Xa inhibitors (2015 –2022)
This article summarizes the small molecule Factor Xainhibitors developed from 2015 to 2022, classifies them according to their scaffolds, focuses on the analysis of their structure-activity relationships, and provides a brief assessment of them.
Source: Frontiers in Pharmacology - February 21, 2023 Category: Drugs & Pharmacology Source Type: research
Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries
CONCLUSIONS: Incidences of intracranial bleeding were generally lower with rivaroxaban than with SOC, whereas incidences of gastrointestinal and urogenital bleeding were generally higher. The safety profile of rivaroxaban for NVAF in routine practice is consistent with findings from randomized controlled trials and other studies.PMID:36795067 | DOI:10.1080/14740338.2023.2181334
Source: Expert Opinion on Drug Safety - February 16, 2023 Category: Drugs & Pharmacology Authors: Luis Alberto Garc ía-Rodríguez Ana Ruig ómez Tania Schink Annemarie Voss Elisabeth Smits Karin M A Swart Yanina Balabanova Kiliana Suzart-Woischnik Gunnar Brobert Ron M C Herings Source Type: research
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis
ConclusionOur meta-analysis demonstrated that in patients with AF and BHV, compared with VKAs, using DOACs was associated with reduced stroke and major bleeding events without an increase of all-cause mortality and any bleeding. In the population younger than 75 years old, DOAC might be more effective in preventing cardiogenic stroke.
Source: European Journal of Clinical Pharmacology - February 16, 2023 Category: Drugs & Pharmacology Source Type: research
Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
Conclusion: NOACs had better long-term risk-benefit profiles than VKAs. While effectiveness was comparable, apixaban was overall associated with a more favorable safety profile followed by dabigatran.
Source: Frontiers in Pharmacology - February 2, 2023 Category: Drugs & Pharmacology Source Type: research
Acetylsalicylic Acid (aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
CONCLUSION: Aspirin use in patients with DM reduces the composite endpoint of CV death, non-fatal MI and stroke compared with a placebo. However, routine use of aspirin for primary prevention among diabetic patients cannot be advised due to the increased risk of major bleeding. These findings suggest careful risk assessment of individual patients.PMID:36718966 | DOI:10.2174/1570161121666230131120544
Source: Current Vascular Pharmacology - January 31, 2023 Category: Drugs & Pharmacology Authors: Shuangbo Liu Janine Eckstein Anna Lam Asim Cheema Source Type: research
Pharmacogenetics of warfarin dosing in Chinese adults with nonvalvular atrial fibrillation
ConclusionGenotype-guided warfarin administration increases the average TTR, reaches higher TTR levels in the early anticoagulant phase, and significantly reduces the risk of ischemic stroke events.
Source: European Journal of Clinical Pharmacology - January 28, 2023 Category: Drugs & Pharmacology Source Type: research
Safety Signal Evaluation of a Risk of Syncope and Dizziness Not Related to Bleeding or Stroke in Direct Oral Anticoagulant-Treated Patients
Clin Ther. 2023 Jan 16:S0149-2918(22)00416-7. doi: 10.1016/j.clinthera.2022.12.010. Online ahead of print.ABSTRACTPURPOSE: In clinical studies, rivaroxaban treatment has been associated with increased incidence of syncope not related to bleeding, anemia, or stroke. The study objective was to evaluate the occurrence of dizziness and/or syncope not related to bleeding, anemia, or stroke in patients treated with direct oral anticoagulants (DOACs).METHODS: A retrospective, observational, comparative study of adult patients diagnosed with atrial fibrillation and treated with DOACs was conducted using digital retrieval of medica...
Source: Clinical Therapeutics - January 18, 2023 Category: Drugs & Pharmacology Authors: Ophir Lavon Daisy Cohen Source Type: research
Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: A prospective, randomized controlled trial
Conclusion: The present study demonstrates that personalized antiplatelet therapy guided by clopidogrel pharmacogenomics and clinical characteristics can significantly improve the net clinical benefit of ischemic stroke or TIA patients during the 90-day treatment period without increasing bleeding risk.
Source: Frontiers in Pharmacology - January 18, 2023 Category: Drugs & Pharmacology Source Type: research
The Frozen Elephant Technique Using a Novel Hybrid Prosthesis for Extensive Aortic Arch Disease: A Multicentre Study
ConclusionsUse of this new-generation hybrid prosthesis for FET was safe and effective. Patient follow-up was largely uneventful given the extent of the procedures performed. In particular, bleeding events were uncommon in this cohort of patients comprising many aortic dissections and re-operative procedures. No increase in oozing was observed.Graphical Abstract
Source: Advances in Therapy - January 12, 2023 Category: Drugs & Pharmacology Source Type: research
Evaluation and subgroup analysis of the efficacy and safety of intensive rosuvastatin therapy combined with dual antiplatelet therapy in patients with acute ischemic stroke
ConclusionsWithout increasing bleeding and statin-associated adverse events, intensive rosuvastatin therapy plus 7-day DAPT significantly reduced the risk of recurrent stroke, especially for subgroups with high-risk factors.Clinical trial registration. China Clinical Trial Registration Center (ChiCTR1800017809).
Source: European Journal of Clinical Pharmacology - December 29, 2022 Category: Drugs & Pharmacology Source Type: research
